In vivo fluorescence imaging of hepatocellular carcinoma xenograft using near-infrared labeled epidermal growth factor receptor (EGFR) peptide

Li, Z.; Zhou, Quan; Zhou, Juan; Duan, Xiyu; Zhu, Jinmin; Wang, T. D.

doi:10.1364/boe.7.003163

Cited by 5 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By targeting the tumor marker integrin αvβ3 receptor with RGD peptide, they accurately delineated HCC margins, and the average size of the detected microtumor lesions was 0.4±0.21 mm with excellent tumor-to-background ratio (TBR) of 4.7±0.21. Li et al (49) emphasized the value of Cy5.5-labeled peptide specific for epidermal growth factor receptor (EGFR) in minimally-invasive surgery of HCC. A compact imaging module was attached to the proximal end of a medical laparoscope, and this integrated imaging methodology measured a mean TBR of 2.99±0.22 from 13 surgically exposed subcutaneous SK-Hep1 human HCC tumors in vivo in 5 mice.…”

Section: Nir-i Fluorescent Probementioning

confidence: 99%

A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma

Zhang¹,

Hu²,

Tian³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Hepatectomy is a main therapeutic strategy for hepatocellular carcinoma (HCC), which requires removal of primary and disseminated tumors and maximum preservation of normal liver tissue. However, in a clinical operation, it is difficult to recognize the tumor tissue and its boundary with the naked eye and palpation, which often leads to insufficient or excessive resection. Near-infrared fluorescence (NIRF) imaging, a non-invasive, real-time, low-cost, and highly sensitive imaging technique has been extensively studied in surgical navigation. With the development of fluorescence imaging system and fluorescent probe, intraoperative tumor detection and margin definition can be achieved, making the operation more accurate.Advances in fluorescence imaging of HCC in the NIR region have focused on the traditional first NIR window (NIR-I, 700-900 nm), and have recently been extended to the second NIR window (NIR-II, 1,000-1,700 nm). Compared with NIR-I imaging, fluorescence imaging in the NIR-II exhibits great advantages, including higher spatial resolution, deeper penetration depth, and lower optical absorption and scattering from biological substrates with minimal tissue autofluorescence. There is no doubt that developing novel NIRF probes for in vivo imaging of HCC has high significance and direct impact on the field of liver surgery.In this article, the development of various NIRF probes for fluorescence image guided HCC hepatectomy is reviewed, and current challenges and potential opportunities of these imaging probes are discussed.

show abstract

Section: Nir-i Fluorescent Probementioning

confidence: 99%

A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma

Zhang¹,

Hu²,

Tian³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…QRH peptide was labeled with Cy5.5 and used to detect spontaneous colonic adenomas that overexpress EGFR in a mouse model with confocal endomicroscopy. [9b] In another study, Li et al [34] developed a novel imaging system by attaching an imaging module containing the optics, filters, and cameras to the proximal end of a surgical laparoscope to collect near-IR fluorescence images. After systemic administration of the Cy5.5labeled QRH peptide (QRH*-Cy5.5) which binds specifically to EGFR, the authors were able to detect fluorescent lesions in vivo in a mouse xenograft model of hepatocellular carcinoma (HCC) based on the EGFR expression of the tumor.…”

Section: Fluorescence Detectionmentioning

confidence: 99%

“…The designed device was promising for fluorescence image-guided surgery of HCC during surgery which improves visualization of tumor lesions (Figure 3). [34] Similarly, some other studies used fluorescently labeled QRH peptide as a contrast agent in confocal endomicroscopy with different designs, such as dual axes confocal [35] and side-viewing confocal endomicroscopy. [36] Another study used a dual-targeting approach for in vivo fluorescence imaging Barrett's neoplasia.…”

Section: Fluorescence Detectionmentioning

confidence: 99%

“…QRH peptide was labeled with Cy5.5 and used to detect spontaneous colonic adenomas that overexpress EGFR in a mouse model with confocal endomicroscopy [9b] . In another study, Li et al [34] . developed a novel imaging system by attaching an imaging module containing the optics, filters, and cameras to the proximal end of a surgical laparoscope to collect near‐IR fluorescence images.…”

Section: Fluorescence Detectionmentioning

confidence: 99%

Section: Fluorescence Detectionmentioning

confidence: 99%

See 2 more Smart Citations

Innovative Diagnostic Peptide‐Based Technologies for Cancer Diagnosis: Focus on EGFR‐Targeting Peptides

et al. 2022

View full text Add to dashboard Cite

Active targeting using biological ligands has emerged as a novel strategy for the targeted delivery of diagnostic agents to tumor cells. Conjugating functional targeting moieties with diagnostic probes can increase their accumulation in tumor cells and tissues, enhancing signal detection and, thus, the sensitivity of diagnosis. Due to their small size, ease of chemical synthesis and site‐specific modification, high tissue penetration, low immunogenicity, rapid blood clearance, low cost, and biosafety, peptides offer several advantages over antibodies and proteins in diagnostic applications. Epidermal growth factor receptor (EGFR) is one of the most promising cancer biomarkers for actively targeting diagnostic and therapeutic agents to tumor cells due to its active involvement and overexpression in various cancers. Several peptides for EGFR‐targeting have been identified in the last decades, which have been obtained by multiple means including derivation from natural proteins, phage display screening, positional scanning synthetic combinatorial library, and in silico screening. Many studies have used these peptides as a targeting moiety for diagnosing different cancers in vitro, in vivo, and in clinical trials. This review summarizes the progress of EGFR‐targeting peptide‐based assays in the molecular diagnosis of cancer.

show abstract

Based on lapatinib innovative near-infrared fluorescent probes targeting HER1/HER2 for in vivo tumors imaging

Lin

et al. 2022

Biosensors and Bioelectronics

View full text Add to dashboard Cite

In vivo fluorescence imaging of hepatocellular carcinoma xenograft using near-infrared labeled epidermal growth factor receptor (EGFR) peptide

Cited by 5 publications

References 16 publications

A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma

A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma

Innovative Diagnostic Peptide‐Based Technologies for Cancer Diagnosis: Focus on EGFR‐Targeting Peptides

Based on lapatinib innovative near-infrared fluorescent probes targeting HER1/HER2 for in vivo tumors imaging

Contact Info

Product

Resources

About